B7-H4在人胶质瘤组织中的表达及其临床意义

Expression of B7-H4 in human glioma tissues and its clinical significance

目的:探讨B7-H4在人胶质瘤组织中的表达及其临床意义。方法:HE染色分析了150例胶质瘤标本病理级别。免疫组化方法检测B7-H4在胶质瘤中的表达,并分析其与临床病理参数及生存时间的关系。结果:HE染色检测150例胶质瘤标本病理级别,结果为I级12例,II级50例,III级39例,IV级49例。150例胶质瘤标本中97例B7-H4高表达,高表达率为64.7%,居于病理级别III～IV级;43例B7-H4低表达,低表达率为28.7%,居于病理级别I～II级。统计学分析提示组织标本中B7-H4的表达与年龄(P<0.01)和病理级别(P<0.01)存在明显相关,与肿瘤的部位没有显著相关性(P>0.05)。B7-H4阳性患者生存期更短(P<0.01),多因素Cox回归分析显示B7-H4、年龄、性别及病理级别均是胶质瘤患者的独立预后因素。结论:B7-H4在多数胶质瘤组织中表达较高,可作为脑胶质瘤患者的独立预后分子标志物和新的治疗靶点。

AIM： To investigate the expression of B7-H4 in human glioma tissues and its clinical significance. METHODS ： The histological staging of 150 cases of human glioma tissues was determined by HE staining. Immunohisto- chemistry was performed to study the protein level of B7-H4 in 150 human glioma specimens. Furthermore, the relation- ships between the expression level of B7-H4 and clinicopathological parameters, as well as patients＇ survival rate, were ana- lyzed. RESULTS： HE staining result indicated that there were 12 cases staged as stage I, 50 cases stage Ⅱ, 39 cases stage Ⅲ and 49 cases stage IV in 150 glioma specimens. Ninety-seven cases highly expressed B7-Hg in total 150 glioma samples with a 64.7% high expression rate. The histological grade of the tissues with high B7-H4 expression was mostly Ⅲ- IV. There were 53 cases with low B7-H4 expression in the total 150 glioma patients with a 35.3% low expression rate. The histological grade of the tissues with low B7-H4 expression was mostly I - Ⅱ. The B7-H4 expression was related to the age of the patients （P 〈 0. 01 ） and the pathological grade of glioma （P 〈 0. 01 ）, but not related to the location of glioma （P 〉 0.05）. Kaplan-Meier survival curves demonstrated that increased B7-H4 expression was associated with shor- ter overall survival time （P 〈 0. 01 ）. Multivariate Cox regression analysis revealed that B7-Hg, age, sex and pathological grade were independent prognostic factors in glioma patients. CONCLUSION： BT-H4 is expressed in most of glioma tis- sues. B7-H4 may be a novel prognostic biomarker and a new target of molecular therapy for gliomas.